Curve Biosciences positions itself as the “Whole-Body Intelligence” company focused on lowering the cost and improving the effectiveness of chronic disease management. Its core product suite pairs the Whole-Body Atlas—a manually curated repository said to be the world’s largest collection of tissue samples labeled by organ and disease state—with AI models to create Whole-Body Blood Tests that can anticipate disease onset and guide therapy choices. The resulting platform aims to give actionable insights to patients, insurers, pharmaceutical companies, and physicians. The company’s executive team includes veterans from Genentech, GRAIL, Natera, Counsyl, and Stanford University, bringing deep expertise in precision diagnostics, product development, and AI. Curve intends to use its newly raised capital to complete clinical validation studies and commercialize its tests. Financially, the company has secured $40 million in Series A funding and has not disclosed any revenue or user figures to date. With this capital, Curve Biosciences plans to scale both its data assets and blood-testing operations to support broader market adoption.

Total raised

$40M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2025